Adoptive Transfer of Activated Immune Cells against Solid Tumors: A Preliminary Study

Elsevier

Available online 27 September 2022, 104616

Cellular ImmunologyHighlights•

Novel cellular therapy against solid tumors.

Preliminary results of specific cellular therapy administration.

Descriptive and inferential statistical analysis.

Evaluation of efficacy and safety of therapy.

AbstractBackground

This study presents preliminary results concerning the effectiveness of a novel immunotherapy in cancer. The proposed adoptive cellular therapy product contains a mixture of effector immune cells, specifically macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes and monoclonal antibody producing plasma cells.

Methods

The results were based on both descriptive and inferential statistical analysis of data concerning 17 cancer patients. Particularly, performance scales such as clinical condition, Karnofsky-Index, ECOG index and symptom’s scale were evaluated post therapy administration (4 months). Furthermore, circulating tumor cells (CTCs) and a specific tumor marker (EpCAM) were measured pre- and post-cellular therapy.

Results

The results revealed a positive evaluation for clinical condition (70.59%), Karnofsky-Index (88.23%), ECOG index (94.12%), and symptoms’ scale (64.70%). In addition, statistically significant reductions were found for both CTCs (p = 0.0016) and EpCAM positive cells (p=0.0005), post-therapy, which were related to large size effects, namely 0.77 and 0.85, respectively. No cytokine storm, anaphylaxis or severe adverse events were observed with 4 months follow up evaluation.

Conclusions

These preliminary results indicate that the proposed cellular therapy can be considered for further studies in clinical trials.

Keywords

Cellular Therapy

Immunotherapy

Cancer

Immune Cells

Autologous Therapy

© 2022 The Author(s). Published by Elsevier Inc.

留言 (0)

沒有登入
gif